Diabetic Neuropathy Market Size - By Disease Type (Proximal, Peripheral, Autonomic and Focal), By Drug Class (Anti-Seizures, Anti-Depressants, Opioid, Non-Steroidal Anti-Inflammatory, and others), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies) and By Region: Global & Forecast, 2024-2033

  • 2023-11-28
  • 204
  • Healthcare & Life Sciences

Market Overview

Diabetic Neuropathy Market is projected to achieve a value of USD 5.23 Billion in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 9.45 Billion by 2033 with a CAGR of 8.1% during the forecast period 2024-2033.

Diabetic neuropathy is a result of diabetes that affects nerves throughout the body due to consistently elevated blood sugar levels. Usually affecting the hands and feet, it presents as a nerve injury that causes tingling, numbness, pain, or weakness. Over time, serious problems affecting digestion, heart rhythm, and even organ function may develop. This illness is brought on by altered metabolism, inflammation, and decreased blood flow, and it impairs nerve signaling. Blood sugar control, medication to relieve symptoms, and lifestyle changes are all necessary to stop diabetes from worsening and developing new complications.

Around the world, diabetes management is regarded as a top priority. The diabetic neuropathy market is expanding since there are more people with diabetes. In addition, rising rates of diabetic neuropathy, heightened consciousness regarding diabetes care, and other factors are compelling major businesses to concentrate on the introduction of new products in the upcoming years. Because of this, throughout the projection period, major players will be concentrating on developing cutting-edge products for the better treatment of diabetic neuropathy. Manufacturers are concentrating on creating mouth spray, powder, transdermal patches, and other products.

According to the current state of the industry, the rising incidence of diabetes worldwide is predicted to cause the global diabetic neuropathy market to expand significantly over the next several years. Furthermore, there has been a significant increase in the prevalence of diabetic neuropathy due to the aging population and the adoption of sedentary lifestyles. Innovative treatment options including gene therapy, stem cell therapy, and RNA interference therapy are among the major trends in the diabetic neuropathy industry. In addition, market expansion is anticipated due to the launch of innovative medications created specially to address neuropathic pain. Further factors expected to fuel market expansion include the need for non-invasive therapies and the growing emphasis on creating customized medications for patients with diabetic neuropathy.

The COVID-19 outbreak has presented difficulties for those suffering from diabetic neuropathy. Because of the body's inflammatory reaction, the virus itself may intensify neuropathic symptoms, possibly leading to worsening nerve pain or other consequences. Lockdowns and restricted access to medical care can interfere with routine exams or treatments, which can affect management plans. Furthermore, the pandemic's stress might raise blood sugar levels, exacerbating symptoms of neuropathy. Neuropathic pain may be influenced by diabetes management, which in turn may be affected by reduced physical activity and changed routines. To lessen the impact on diabetic neuropathy in the face of these pandemic-related issues, telehealth service adaptation and strict diabetes care become essential.

Market Scope

Report Attributes


Market Size in 2023

USD 5.23 Billion

Market Forecast in 2033

USD 9.45 Billion

CAGR % 2024-2033


Base Year


Historic Data


Forecast Period


Report USP

Production, Consumption, company share, company heatmap, company production capacity, growth factors and more

Segments Covered

By Disease Type, By Drug Class, By Distribution Channel and By Region

Growth Drivers

Increasing Awareness and Education

Technological Innovations in Treatment Devices

Research and Development in Therapeutics

Regional Scope

North America, Europe, APAC, South America and Middle East and Africa

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria

Key Companies

GlaxoSmithKline plc., Abbott, Eli Lilly and Company, Astellas Pharma US, Inc., F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., Pfizer Inc, Lupin Pharmaceuticals, Inc. and Others.

Market Dynamics

Market Drivers

Increasing prevalence of diabetes

The diabetic neuropathy market is expanding due in large part to the increasing incidence of diabetes. Diabetic neuropathy, a common consequence of diabetes, is becoming more widespread as the disease spreads over the world. The market is growing at a substantial rate because of diabetic neuropathy, which is defined as nerve damage brought on by persistently high blood sugar levels. The increase in diabetes cases fuels the need for neuropathy care and treatment alternatives, which in turn encourages innovation in medications and medical equipment. The market is growing because there is an urgent need for practical solutions to deal with the growing number of people with diabetes who are experiencing diabetic neuropathy.

Growing the Number of Product Approvals

The diabetic neuropathy market is expanding as a result of more product approvals. Increased therapeutic choices are shaping market dynamics as regulatory bodies approve new drugs and devices to treat diabetic neuropathy. Innovation and competitiveness among producers are fostered by the expanding list of permitted items, which is a reflection of research and development developments. In addition to improving patient care, this flood of authorized solutions draws capital and propels industry growth. The increase in product approvals is a reaction to the growing incidence of diabetic neuropathy, providing medical practitioners with a more comprehensive toolkit of efficacious interventions and advancing the market as a whole.

Market Restrains

High Research and development costs for new therapies and medications

The diabetic neuropathy market is constrained by the high expenses associated with developing novel treatments and pharmaceuticals. Because diabetic neuropathy is so complex, it will take a lot of research to create novel, efficient treatments. Smaller pharmaceutical businesses find it difficult to enter the market since preclinical research, clinical trials, and regulatory compliance require significant financial inputs. Higher R&D expenses may result in more expensive products when they first hit the market, which would make them less affordable for patients and healthcare systems. This financial obstacle might slow the development of novel treatments and make it more difficult for the market to quickly respond to the rising incidence of diabetic neuropathy.

Market- By Disease Type Analysis

By Disease Type, the Diabetic Neuropathy Market is Categories into Proximal, Peripheral, Autonomic and Focal, Others. The Peripheral segment accounts for the largest share of around 70% in 2022.

This is because peripheral neuropathy, which affects about 50% of diabetic patients, is the most prevalent kind of diabetic neuropathy. Peripheral neuropathy is predicted to be increasing in the upcoming years due to a projected sharp rise in the global diabetes patient population. As a result, there will be a greater need for peripheral neuropathy therapies such painkillers, physical therapy, and surgery.

Market- By Drug Class Analysis

By Drug Class, the Diabetic Neuropathy Market is Categories into Anti-Seizures, Anti-Depressants, Opioid, Non-Steroidal Anti-Inflammatory, and others. The Anti-Seizures segment accounts for the largest share of around 45% in 2022.

The market for ASDs in diabetic neuropathy is driven by these drug’s established use in neurology, acceptable safety profile, cost-effectiveness, and mechanistic approach to pain control. ASDs are a beneficial therapy option for patients with diabetic neuropathy because of these factors.

Market- By Distribution Channel Analysis

By Distribution Channel, the Diabetic Neuropathy Market is Categories into Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies. The Hospital Pharmacies segment accounts for the largest share of around 65% in 2022.

Hospital pharmacists are skilled in treating complicated medical disorders such as diabetic neuropathy because of their specific training and experience. They can guarantee that patients are taking the appropriate meds at the appropriate dosages and offer thorough medication counseling.

Market-Regional Analysis

North America dominate the Diabetic Neuropathy Market with the highest revenue generating market with share of more than 47%. The high rate of diabetes, growing knowledge of diabetic neuropathy, and advantageous reimbursement practices are the main factors in the area which dominate the market. With more than 60% of the North American market share, the United States is expected to be the largest market in the area.

Europe is expected to become the second-largest market due to factors such as the aging population, the incidence of diabetes, and the rising cost of healthcare. It is expected that Germany and France will be the primary markets in the area.

The Asia Pacific region is predicted to grow at the quickest rate due to increased urbanization, improved healthcare infrastructure, and rising incidence of diabetes. It is anticipated that the two main forces propelling regional expansion will be China and India.

Competitive Analysis

The Diabetic Neuropathy Market is dominated by a few large companies, such as GlaxoSmithKline plc., Abbott, Eli Lilly and Company, Astellas Pharma US, Inc., F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., Pfizer Inc, Lupin Pharmaceuticals, Inc. and Others.

There are some of the key trends that are shaping the competitive landscape of the Diabetic Neuropathy Market.

April 2019, Japan's Tarlige pills, marketed under the generic name microgabalin bestilate, were introduced by Daiichi Sankyo to relieve the pain experienced by individuals with peripheral diabetic neuropathy.

October 2018, A phase III clinical trial called AKCEA-TTR-L has been initiated by Ionis Pharmaceuticals and Akcea Therapeutics to treat polyneuropathy in patients with hereditary TTR (hATTR) amyloidosis.

Research Report Following Segments:

By Disease Type

·         Proximal

·         Peripheral

·         Autonomic and Focal

By Drug Class

·         Anti-Seizures

·         Anti-Depressants

·         Opioid

·         Non-Steroidal Anti-Inflammatory

·         others

By Distribution Channel

·         Hospital Pharmacies

·         Retails Pharmacies & Stores

·         Online Pharmacies

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process

We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).


The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.

Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.

Frequently Asked Questions

What is the market size of Diabetic Neuropathy Market in 2022?

Diabetic Neuropathy Market was valued at USD 4.85 Billion in 2022.

What is the growth rate for the Diabetic Neuropathy Market?

Diabetic Neuropathy Market size will increase at approximate CAGR of 8.1% during the forecasted period.

Which are the top companies operating within the market?

Major companies operating within the Diabetic Neuropathy Market are GlaxoSmithKline plc., Abbott, Eli Lilly and Company, Astellas Pharma US, Inc., F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., Pfizer Inc, Lupin Pharmaceuticals, Inc. and Others.

Which region dominates the Diabetic Neuropathy Market?

North America dominates the market with an active share of 47%.


Select a license type that suits your business needs

Single User Access

US $3950

Only Three Thousand Nine Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $4950

Only Four Thousand Nine Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $5950

Only Five Thousand Nine Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI